A
Ajax Therapeutics
Developing targeted therapies for hematologic cancers through innovative cytokine signaling pathways
About Ajax Therapeutics
Ajax Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for hematologic cancers. Leveraging advances in molecular genetics and biology, Ajax targets key cytokine signaling pathways to create uniquely selective treatments. The company operates in the biopharmaceutical market, primarily serving patients with blood cancers. Ajax's business model involves research and development of proprietary drugs, which are then brought to market through partnerships and collaborations with leading medical institutions and investors. Revenue is generated through licensing agreements, research collaborations, and eventual drug sales. Key clients include healthcare providers, research institutions, and pharmaceutical companies. Ajax has secured funding from prominent investors such as EcoR1 Capital LLC, Boxer Capital, and Inning One Ventures, and collaborates with renowned institutions like Memorial Sloan Kettering Cancer Center and NYU Langone Health. The company is led by a seasoned board of directors with extensive experience in drug discovery and development.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 79.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $2.3B | $2.3B | Eli Lilly | ↗ |
| SERIES COther financing | May 2024 | $95M | $380M | Goldman Sachs · Schrodinger · Vivo Capital · Eli Lilly | ↗ |
Growth signals
Latest recorded traffic for Ajax Therapeutics is 3.3K monthly website visits, down 17.5% over the last three months. Ajax Therapeutics's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Schrodinger
Boxer Capital
NYU Langone Health- IVInning One Ventures
Memorial Sloan - Kettering Cancer Center
EcoR1 Capital
Series B and later5 investors entered at this stage
Goldman Sachs
Vivo Capital
Eli Lilly
RA Capital Management
Point72
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ajax Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ajax Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.